FluBlok, a next generation influenza vaccine manufactured in insect cells.

FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing process presents the possibility for safe and expeditious vaccine production. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. The high purity of the antigen enables administration at higher doses without a significant increase in side-effects in human subjects. The insect cell-baculovirus production technology is particularly suitable for influenza where annual adjustment of the vaccine is required. The baculovirus-insect expression system is generally considered a safe production system, with limited growth potential for adventitious agents. Still regulators question and challenge the safety of this novel cell substrate as FluBlok continues to advance toward product approval. This review provides an overview of cell substrate characterization for expresSF cell line used for the manufacturing of FluBlok. In addition, this review includes an update on the clinical development of FluBlok. The highly purified protein vaccine, administered at three times higher antigen content than TIV, is well tolerated and results in stronger immunogenicity, a long lasting immune response and provides cross-protection against drift influenza viruses.

[1]  M. Cox,et al.  Production of a novel influenza vaccine using insect cells: protection against drifted strains , 2007, Influenza and other respiratory viruses.

[2]  L. A. Ball,et al.  The Insect Viruses , 2012, The Viruses.

[3]  R. Couch,et al.  Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly , 1996, Clinical and diagnostic laboratory immunology.

[4]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[5]  Timothy M Rose,et al.  CODEHOP-mediated PCR – A powerful technique for the identification and characterization of viral genomes , 2005, Virology Journal.

[6]  B. Parekh,et al.  Root cause investigation of a viral contamination incident occurred during master cell bank (MCB) testing and characterization--a case study. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[7]  M. Cox,et al.  Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine , 2005, Vaccine.

[8]  A. Pélisson,et al.  Evolution and phylogeny of insect endogenous retroviruses , 2001, BMC Evolutionary Biology.

[9]  G. Stacey,et al.  WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[10]  Clifton E McPherson.  Development of a novel recombinant influenza vaccine in insect cells. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[11]  R. Webster,et al.  Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus , 2005, Archives of Virology.

[12]  S. Henikoff,et al.  Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences. , 1998, Nucleic acids research.

[13]  D. Persing,et al.  Consensus-degenerate hybrid oligonucleotide primers (CODEHOP) for the detection of novel papillomaviruses and their application to esophageal and tonsillar carcinomas. , 2005, Journal of virological methods.

[14]  Kathy Holtz,et al.  Production of a Recombinant Influenza Vaccine Using the Baculovirus Expression Vector System , 2003 .

[15]  G. J. Tompkins,et al.  The establishment of two cell lines from the insectspodoptera frugiperda (lepidoptera; noctuidae) , 1977, In Vitro.

[16]  Keiji Fukuda,et al.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[17]  R. Webster,et al.  Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. , 1986, Virus research.

[18]  S. Baron,et al.  5-iododeoxyuridine potentiation of the replication in vitro of several unrelated RNA and DNA viruses , 1975, Science.

[19]  G. Kuno,et al.  Biological Transmission of Arboviruses: Reexamination of and New Insights into Components, Mechanisms, and Unique Traits as Well as Their Evolutionary Trends , 2005, Clinical Microbiology Reviews.

[20]  P. Scotti,et al.  Latent Infection of a New Alphanodavirus in an Insect Cell Line , 2007, Journal of Virology.

[21]  Nims Rw.  Detection of adventitious viruses in biologicals--a rare occurrence. , 2006 .

[22]  Khan As,et al.  Pert analysis of endogenous retroviruses induced from K-BALB mouse cells treated with 5-iododeoxyuridine: a potential strategy for detection of inducible retroviruses from vaccine cell substrates. , 2001 .

[23]  F. Hayden,et al.  Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. , 2007, JAMA.

[24]  J. Treanor,et al.  FluBlok, a recombinant hemagglutinin influenza vaccine , 2008, Influenza and other respiratory viruses.

[25]  R. Couch,et al.  High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults , 1994, Journal of clinical microbiology.

[26]  R. Nims.  Detection of adventitious viruses in biologicals--a rare occurrence. , 2006, Developments in biologicals.

[27]  C. Marcus-Sekura,et al.  Susceptibility of the Sf9 insect cell line to infection with adventitious viruses. , 1994, Biologicals : journal of the International Association of Biological Standardization.

[28]  A. Levine,et al.  Regulation of viral transcription in cells infected with iododeoxyuridine-substituted simian virus 40 as a model for the activation by iododeoxyuridine of latent viral genomes. , 1981, Cancer research.

[29]  A. Watts,et al.  Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. , 1994, Vaccine.

[30]  Michael L. Wang,et al.  Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. , 2006, The Journal of infectious diseases.

[31]  R. Mutharasan,et al.  Protein response of insect cells to bioreactor environmental stresses. , 2005, Journal of biotechnology.

[32]  R. Webster,et al.  Standardization of inactivated H5N2 influenza vaccine and efficacy against lethal A/Chicken/Pennsylvania/1370/83 infection. , 1985, Avian diseases.

[33]  J. Sears,et al.  Early detection of endogenous retroviruses in chemically induced mouse cells. , 2001, Virus Research.

[34]  R. Couch,et al.  Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. , 2006, The Journal of infectious diseases.